ONCE-DAILY RHOPRESSA (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% Trademark Information

Trademark by Aerie Pharmaceuticals, Inc.

PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

Classification Information

Intent to Use Trademark - Applicant has not submitted proof of use in commerce the the USPTO.

Primary Class: Class Details:
Class (005)
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
First Use Anywhere:: Not provided
First Use In Commerce: Not provided
General Information
Word mark: ONCE-DAILY RHOPRESSA (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%
Status/Status Date:
ABANDONED - NO STATEMENT OF USE FILED
4/19/2021
Serial Number: 87784530
Filing Date: 2/5/2018
Registration Number: NOT AVAILABLE
Registration Date: NOT AVAILABLE
Goods and Services: PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION
Mark Description: The mark consists of the word "RHOPRESSA" with a half circle above and beneath the "RHO" portion of the word "RHOPRESSA" and the word "ONCE-DAILY" above "RHOPRESSA" and the words "(NETARSUDIL OPHTHALMIC SOLUTION) 0.02%" beneath "RHOPRESSA".
Type Of Mark: TradeMark
Published For Opposition Date: 1/22/2019
Last Applicant/Owner:
Aerie Pharmaceuticals, Inc.
Irvine, CA 92688
Mark Drawing Code: Drawing/Design + Words
Design Search:
Semi - circles (Geometric figures and solids - Coding and searching guide) see more design...
Register Type: Principal
Disclaimer: ("ONCE-DAILY", "NETARSUDIL OPHTHALMIC SOLUTION 0.02%")
Correspondent:
WOO ALLEN LAW LLP
3398 Carmel Mountain Road, Ste. 250
SAN DIEGO CA 92121
Current Status:
ABANDONED - NO STATEMENT OF USE FILED
4/19/2021
Correspondent Search:
MELISSA W. WOO-ALLEN is a correspondent of ONCE-DAILY RHOPRESSA (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% trademark.
Current Overall Rating:
RatingRatingRatingRatingRating

(0 review)

As seen on